ARA320822 is an experimental erythropoietin derived peptide developed to deliver tissue protective and anti inflammatory effects without stimulating red blood cell production. It is part of Araim Pharmaceuticals’ non hematopoietic erythropoietin mimetic research program, which focuses on separating the cytoprotective and immune regulating properties of erythropoietin from its erythropoietic function. Preclinical findings suggest ARA320822 may help reduce inflammatory responses, limit oxidative and ischemic cellular injury, and promote tissue repair, while potentially lowering the risk of side effects such as elevated hemoglobin levels or thrombosis that are associated with traditional erythropoietin based treatments.